An observational study in Sepsis, sponsored by Unimed Volta Redonda. Status unknown at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-08-04.
Sponsored by Unimed Volta Redonda · Observational
Research in the databases Lilacs, BIREME, SciELO by the terms: systemic inflammatory response syndrome (SIRS), sepsis, severe sepsis and septic shock and their equivalents in the English language. Selection of the main articles of the last five years to study and contextualize the reality presented since the implantation of the HUVR sepsis protocol. Statistical analysis of data since the implementation of the sepsis protocol in the HUVR, in July 2014 until June 2016.
This is the only study on the registry with Unimed Volta Redonda as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Patients over 18 years of age hospitalized with suspected or confirmed diagnosis of sepsis at HUVR.
All individuals who had a confirmed or suspected sepsis diagnosis and had a sepsis protocol completed during the study period.
-
Exclusion Criteria:
Individuals with confirmed or suspected sepsis in the study period who did not complete the protocol.
Individuals under the age of 18
-
2015 - Individuals with a diagnosis of sepsis from June 2014 to May 2015
Other: Sepsis protocol
2016 -Individuals with a diagnosis of sepsis from June 2015 to May 2016
Other: Sepsis protocol
Adherence to the sepsis protocol
Adherence to the sepsis protocol
Implementation of the measures recommended in the sepsis protocol
Time frame: From 2014 to 2016
Sepsis mortality rate
Assessment of the evolution of the sepsis mortality rate
Time frame: From 2014 to 2016
Plan to share: No
No publications or documents are linked to this record.
This study is status unknown, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.